In the field of diabetes treatment, stem cell therapy is transitioning from laboratory research to clinical application, achieving remarkable progress particularly in the management of Type 2 Diabetes (T2D). In 2025, numerous global studies and clinical trials were published, revealing the potential of stem cells in pancreatic islet function restoration, glycemic control, and immune modulation.
I. Research Trends: Multidimensional Exploration of Stem Cell Therapy
Research on stem cell therapy for T2D primarily focuses on the following directions:
Mesenchymal Stem Cell (MSC) TherapyMSCs are widely utilized to repair damaged pancreatic β-cells, remodel the islet microenvironment, and regulate immune responses. Multiple clinical studies confirm that MSC infusion significantly reduces glycated hemoglobin (HbA1c), lowers insulin requirements, and demonstrates an excellent safety profile.
Autologous Stem Cell Regenerative TherapyA research team at a Shanghai hospital successfully treated multiple patients with severe T2D using autologous stem cell regenerative therapy, achieving complete insulin independence.
Allogeneic Regenerative Islet Cell TherapyIn April 2025, the "Allogeneic Human Regenerative Islet Injection," developed by a Shanghai medical team, obtained clinical trial approval. It marks China’s first and the world’s second allogeneic universal regenerative islet product entering clinical research.II. Mechanisms of Action: Multiple Pathways from Repair to Regeneration
Core therapeutic mechanisms for T2D include:
Immune Modulation: Attenuate islet inflammation and preserve endocrine function via immunoregulation.
Cellular Regeneration: Differentiate into pancreatic progenitor cells to facilitate β-cell renewal.
Paracrine Effects: Secrete trophic factors to enhance islet cell survival and functional recovery.These synergistic mechanisms restore physiological islet function and optimize long-term glycemic homeostasis.
III. Global Clinical Research Progress
China
A Shanghai hospital team achieved complete insulin independence in severe T2D patients via autologous stem cell regenerative therapy.
Peking University Shenzhen Hospital demonstrated that intravenous umbilical cord MSC infusion significantly improved fasting blood glucose, HbA1c, and gradually restored C-peptide levels in T2D cohorts.
A joint team from an affiliated geriatric hospital, school of basic medicine, and first affiliated hospital of a Nanjing medical university published research in December 2025. The study validated that human amniotic MSC-derived small extracellular vesicles (hAMSC-sEVs) induced diabetes remission in aged diabetic mouse models. For the first time, it directly linked mitochondrial calcium signaling to β-cell senescence, identifying novel molecular targets for age-related metabolic disorders.
United States
Vertex Pharmaceuticals’ VX-880 trial reported 83% of participants achieved full insulin independence with profound HbA1c reduction, proving stem cell therapy’s revolutionary potential in diabetes reversal.
South Korea
A 2023 Korean study on autologous adipose MSC intravenous infusion for T2D showed an average 2.1 mmol/L reduction in fasting blood glucose after 24 weeks, alongside improved postprandial glucose and HbA1c—offering an alternative for patients refractory to conventional management.
Brazil & United States
A collaborative trial for Type 1 Diabetes enrolled 15 volunteers (14–31 years old). Post-treatment, 11 participants immediately produced endogenous insulin without exogenous supplementation; 2 recipients maintained low-dose insulin for over one year before achieving injection freedom.
The first trial participant has remained insulin-free for 3 years. Mild adverse events (nausea, vomiting, alopecia) were transient with no severe safety concerns.
Japan
NOA Hospital developed innovative minimally invasive adipose harvesting technology, generating large-scale high-quality stem cells from small tissue biopsies. This protocol reduces costs, enhances stem cell viability, and maximizes therapeutic efficacy.